Hae Su Kim 1 , 2 , Ji Yun Lee 1 , Su Jin Lee 1 , Ho Yeong Lim 1 , Hyun Hwan Sung 3 , Hwang Gyun Jeon 3 , Byong Chang Jeong 3 , Seong Il Seo 3 , Seong Soo Jeon 3 , Hyun Moo Lee 3 , Han-Yong Choi 3 , Se Hoon Park , 1
22 August 2017
The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC).
We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m 2 on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m 2 every 3 weeks for patients with CRPC ( n = 24). After Oct 2013, all chemotherapy-naïve patients with CRPC received a 40 mg/m 2 biweekly regimen ( n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline.
The baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups.